Galectin Therapeutics (GALT) vs Turn Therapeutics (TTRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Turn Therapeutics (TTRX) has outperformed Galectin Therapeutics (GALT) over the past year, gaining 147.6% versus a loss of 49.7%. Galectin Therapeutics is the larger company by market cap ($271.4 million vs $247.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GALT | TTRX |
|---|---|---|
| Share price | $2.69 | $8.10 |
| Market cap | $271.35M | $247.49M |
| 1-day change | -4.27% | -6.31% |
| YTD return | -35.34% | +105.46% |
| 1-year return | -49.72% | +147.55% |
| 5-year return | +4.67% | — |
| EPS (TTM) | $-0.32 | $-0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-30.84M | $-3.19M |
| 52-week high | $7.13 | $16.45 |
| 52-week low | $2.03 | $2.70 |
| Distance from 52-week high | -62.27% | -50.79% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +308.92% | +208.83% |
| Average volume | 252.31K | 119.32K |
| Shares outstanding | 100.88M | 30.57M |
| Employees | 9 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TTRX has outperformed GALT by 197.3 percentage points over the past year.
About Galectin Therapeutics
GALT stock →Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About Turn Therapeutics
TTRX stock →Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
GALT vs TTRX FAQ
Which is bigger, Galectin Therapeutics or Turn Therapeutics?
Galectin Therapeutics (GALT) is larger, with a market capitalization of $271.35M compared with $247.49M for Turn Therapeutics (TTRX).
Which stock has performed better over the past year, GALT or TTRX?
TTRX returned +147.55% over the past 12 months, compared with -49.72% for GALT (price return, excluding dividends). Past performance does not predict future results.
Are Galectin Therapeutics and Turn Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.